Akston Biosciences Receives U.S. Patent for Once-A-Week Human Insulin
BEVERLY, Mass. – August 9, 2022 – Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced that it has recently been granted U.S. patent 11,352,407. The patent covers recombinantly manufactured ultra-long acting insulin Fc-fusion proteins for use as once-a-week insulin treatments for diabetes. These insulin Fc-fusion proteins comprise an insulin polypeptide connected via a peptide linker to an Fc-fragment of human origin.
This is the first patent granted to Akston covering once-a-week insulin Fc-fusion proteins for treating human diabetes and the lead compound covered by it, AKS-440, is in manufacturing development at Akston’s Beverly, Massachusetts facility. AKS-440 was designed using Akston’s proprietary Fc-fusion protein platform, which has been used to rapidly and efficiently generate candidate compounds for a diverse set of disease indications.
The company has previously been granted patents in both the U.S, and Europe covering once-a-week insulins for treating canine and feline diabetes. Akston has 17 issued patents world-wide covering not only these insulin therapy candidates but also a candidate in development designed to delay or prevent autoimmune diabetes, and a novel COVID-19 vaccine. The veterinary insulins have been licensed to Dechra Pharmaceuticals PLC and the vaccine has been licensed to Biolexis, a division of the Strides Group, which plans to launch it as AmbiVax-C™ in global markets.
“This new patent demonstrates the value of Akston’s proprietary Fc-fusion protein platform,” said Todd Zion, Ph.D., President & CEO of Akston Biosciences. “We utilize the platform to tailor the different components of an Fc-fusion protein to optimize safety, efficacy, and manufacturability. Once a group of promising candidates is found, variants can be designed, synthesized, and tested to improve overall performance through a rapid and iterative process. This can significantly reduce the time and cost of developing vaccines and therapies.”
About Akston Biosciences Akston Biosciences Corporation leverages its novel Fc-fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co.), Akston owns and operates a GMP biologics cleanroom facility that manufactures kilogram-scale batches of drug substance. This, along with its research and process development laboratories, are located at its Beverly, Mass. location. Additional information is available at akstonbio.com.
Birnbach Communications for Akston Biosciences